The concepts of dominance and recessiveness (or recessivity), originally formulated by Mendel,' are so fundamental to genetics that they are often taken for granted. But 1) .
A potential source of confusion when considering dominance phenomena in human genetic disease, is that only the wild type and heterozygous mutant phenotypes are generally encountered. Examples of homozygous mutants both for relatively common disorders (thalassaemia, familial hypercholesterolaemia) and rarer conditions (achondroplasia, piebaldism) indicate that the phenotype of the homozygote usually tends to be more severe than the heterozygote, hence the wild type and mutant alleles are, strictly speaking, semidominant.6 The Huntington's disease mutation provides an unusual instance of a mutant allele that is truly dominant to wild type in that homozygotes appear no more severely affected than heterozygotes7-9 ( fig 1) . Although it is interesting to speculate on the differences in mechanism giving rise to semidominance and complete dominance, there are insufficient molecular data to attempt a synthesis. The more simple, but perhaps more type. " For example, insertional inactivation by random integration of retroviral DNA into the mouse genome produces recessive and dominant phenotypes with a ratio of about 10-20:1.12 13 The search for an explanation of the recessive behaviour of most mutations generated a lively debate in the 1930s between Sewall Wright, who believed that it arose intrinsically from the physiology of gene action, and RA Fisher, who proposed that the accumulation of modifier alleles at other loci was responsible. Fisher's theory has now generally lost favour, and Orr'4 showed that in the alga Chlamydomonas, which is usually haploid (so that Fisherian selection cannot apply), most mutations nevertheless showed recessive behaviour when examined in a transiently diploid background, supporting Wright's theory. Indeed, diploidy may have evolved because it protects against recessive mutations. '5'7 Thus it is dominance, rather than recessiveness, that demands special explanation; but why should the 'default' state of mutations be recessive?
The usual explanation is as follows. The most likely effects of a random gene mutation are that it will either be neutral (normal phenotype) or inactivating. If the latter, the question is whether the inactivation would be clinically manifest in the heterozygote (dominance or semidominance, specifically, haploinsuffiMuller's classification ciency), or only in the homozygote (recessiveness). In 1981 Kacser and Burns'8 proposed a theory of metabolic fluxes to explain why most inborn errors of metabolism are recessive. Assuming that a metabolic pathway has many non-rate limiting steps, control of flux at any particular point in a pathway will be small. Hence, many pathways show a saturable relationship between enzyme level and metabolic flux, with fluxes fully saturated at wild type enzyme level; a 50% reduction in enzyme activity would therefore cause little reduction in flux below its saturation level.
Although this theory fits metabolic pathways well, it is not applicable to critical rate limiting steps of such pathways, nor to mutations causing qualitatively altered function, especially when structural or controlling/signalling proteins are involved. It is perhaps not surprising that most dominant mutants belong to one of these latter categories, and frequently involve developmental malformations.
An additional explanation for the rarity of dominant mutations is suggested by work on the nematode Caenorhabditis elegans. Recessive mutations at a series of loci termed smg may alter the behaviour of mutations at other loci from recessive to dominant (cryptic dominance). It seems that the wild type smg loci encode proteins that can recognise and selectively degrade many mutant mRNA species, forming part of a mutant surveillance system.'920 The relevance of this finding to humans is not yet clear.
Finally, note that although the number of known recessive conditions in the human may considerably underestimate the total, the true figure is unlikely to approach the total number of genes. There is a growing list of murine genes for which targeted disruption is not associated with any phenotypic abnormality in transgenic mice.21 A similar situation applies to the mutational spectrum in C elegans, and it is noteworthy that dominant "gain of function" mutants exist at several loci for which the homozygous null phenotype is entirely nor- and GCPS are examples) and the phenotype may be sensitive to the genetic background.
To understand the mechanisms of dosage sensitivity in this "regulatory" group requires a detailed knowledge of the molecular interactions involved, something not yet achieved for any human gene. However, simpler organisms provide some excellent model systems. For instance, sex determination in Drosophila requires the ability to distinguish between X:autosomal ratios of 1 in females and 0 5 in males. This may be achieved by titration of "numerator" X chromosome genes against "denominator" autosomal ones, possibly by competition of the cognate proteins for binding to a regulatory DNA sequence.'9 Further insight may be gained by studies of morphogenic proteins, for example the Drosophila transcription factor dorsal (dl), which is distributed in a nuclear concentration gradient along the dorsoventral axis of the early embryo. A fairly specific illustration of loss of temporal regulation is provided by hereditary persistence of fetal haemoglobin (HPFH). Known causes include point mutation of the y globin promoter, which alters binding of the erythroid transcription factor GATA-1,49 certain 3' deletions encompassing the 6 and P globin genes,50 and alterations of unidentified trans acting factors. The effect of all these mutations is to abrogate the normal switch from expression of y to 6 and 1 globin, which occurs around the time of birth. The resulting HPFH dominantly ameliorates the effects of 1 thalassaemia mutations.
An example of ectopic expression is provided by the contrabithorax (Cbx) mutations of Drosophila, which involve the ultrabithorax (Ubx) gene, normally expressed in the posterior part of the embryo with an anterior boundary in the third thoracic segment (T3 At a simplistic level it is easy to understand why mutations of structural proteins are frequently dominant: admixture of normal and abnormal structural components will disrupt the integrity of the overall structure on a "weak links in a chain" principle. Careful cell biochemical analysis shows a more complex picture: additional modulators of the abnormal phenotype will include mRNA stability, and the degree of abnormality in cellular processing, secretion, and extracellular incorporation into mature fibrils, of the nascent protein. Mutations Position effect variegation in Drosophila is the variable reduction in expression of a gene juxtaposed to heterochromatin by chromosome rearrangement. Variegating mutations are generally recessive in that they reduce expression only from the rearranged (cis) chromosome. The brown locus is unusual in that expression is also reduced from the normal (trans) allele. This dominant effect seems to depend on somatic pairing between the homologous chromosomes, but the mechanisms of this and other 'trans sensing' effects are still uncertain. 102 103 The phenomenon of nucleolar dominance in wheat reflects the relative expression of tandem ribosomal DNA from allelic loci. Expression at an individual locus correlates with the number of upstream regulatory sequences. These appear to compete for binding to limiting amounts of an activating protein, so that the more repeats present, the greater the likelihood of activation.'04 Segregation distortion loci subvert the normal pattern of 1:1 gametic segregation, leading to meiotic drive. This may occur either at meiosis, when some property of the general structure or size of a chromosome gives it a replication advantage on the spindle (chromosomal drive), or postmeiotically, when direct competition between the gametes occurs (genic drive).'05 This may allow disadvantageous mutations to spread through the population, by virtue of close linkage to the drive locus. A well known example is the t complex of mouse.
Unlinked non-complementation occurs when heterozygous mutations occur at two genes coding for interacting proteins. Whereas the heterozygous state for either locus on its own is silent, concurrent mutations at both loci cause the phenotypic threshold to be exceeded, and the disease becomes manifest. Examples include the interaction of a and 3 tubulin mutations in Drosophila'06 and, more speculatively, the enhanced severity of dystrophin mutations in trans to an abnormal allele for autosomal recessive Fukuyama congenital muscular dystrophy. 107 An '4 is much more likely to be successful in this group than in the "gain of function" categories. By contrast, acquired chromosomal abnormalities in neoplasia may often pinpoint specific oncogenes involved in "gain of function" transformation. The phenotype associated with missense mutations will usually be critically dependent on their exact position and nature, except in structural proteins; hence multiple, independent point mutations as a cause of dominant disease are most commonly encountered in such proteins.
In understanding mechanisms of cancer, the dominant negative effects illustrated for p53 may occur in other tumour suppressor genes. For instance, germline mutations of the APC gene cause familial adenomatous polyposis/ Gardner's syndrome, and somatic mutations occur in sporadic colon cancer. The amino acid sequence of APC predicts that it will form coiled coils, structural elements that permit oligomerisation. 15 116 The majority of APC mutants, both germline and somatic, are missense17 118 and some could disrupt normal oligomers to give dominant negative effects. Analysis of the particular mutations present may therefore guide prognosis.
The mechanisms of dominance in conditions associated with unstable triplet repeats (for example, fragile X syndrome, myotonic dystrophy, and Huntington's disease) are not yet clear, and probably heterogeneous, with effects owing to alterations in both mRNA expression and protein function. Although the (CGG)n expansion in the fragile X syndrome is associated with DNA methylation and absence of FMR-1 gene expression,' 9 in myotonic dystrophy, DMK alleles containing (CTG)n expansions may actually be overexpressed'20 (although this is disputed'2' 122). Other potential variables are whether the expanded triplet lies in the coding or non-coding region of the protein, and the sequence of the repeat itself. '23 Complete elucidation of the mechanisms of dominance associated with triplet repeat expansion may well yield some surprises.
Finally, an understanding of the molecular mechanism of a disease is a prerequisite for attempting gene therapy. Nearly all diseases currently targeted for gene therapy are recessive,'24 in which the goal is simply to replace the missing product. It should be evident that most categories of dominant disease pose a formidable challenge to gene therapy, but already the "molecular engineers" are contemplating strategies to overcome these problems. Examples include antisense RNA therapy to antagonise selectively the action of dominant negative mutants; or conversely, the introduction of such mutants to counteract the effects of increased mRNA expression or protein activity.
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